Study for collection of Aflibercept data in Routine Practice (CODEX)
The French CODEX study is designed as a national database to describe, in routine medical practice, functional and anatomical responses to intravitreal Aflibercept injection, in a large population of anti-VGEF-naïve patients presenting with wet Age-related Macular Degeneration (wAMD), Central Retinal Vein Occlusion (CRVO),Branch Retinal Vein Occlusion(BRVO), or Diabetic Macular Edema (DME). This national database will gather databases from French private and public ophthalmologic centers.
- Aged ≥18 years old - Anti-VEGF (Vascular Endothelial Growth Factor) treatment naïve - Intravitreal (IVT) aflibercept injection treatment follows the recommendations made within the EYLEA Summary of Product Characteristics - Diagnosed with wAMD (wet Age-related Macular Degeneration), macular edema following CRVO (Central Retinal Vein Occlusion), macular edema following BRVO (Branch Retinal Vein Occlusion), or DME (Diabetic Macular Edema).
- Who have any contraindications listed in the EYLEA Summary of Product characteristics - Participating in an investigational program with interventions outside of routine clinical practice.
Many Locations, France
E-mail: [email protected]
Phone: (+)1-888-84 22937
CODEX:Collection of Aflibercept data in Routine Practice